SOPHIA ANTIPOLIS, France – May 30, 2025 │ CytomX Therapeutics announced positive Phase 1 data for its Epithelial Cell Adhesion Molecule (EpCAM) PROBODY® Antibody Drug Conjugate candidate, CX-2051, in advanced Colorectal Cancer (CRC). CytomX Therapeutics: precision oncology through Probody® innovation CytomX Therapeutics is based in South San Francisco, California. It was founded in 2008 by[…]
SOPHIA ANTIPOLIS, France – April 11th, 2025 │ On March 19th, 2025, a collaboration was announced between Oxford BioTherapeutics (OBT) and Roche to discover novel potentially first-in-class antibody-based therapeutics for the treatment of cancer. Targets will be identified via the OGAP®-Verify discovery platform of OBT, a proprietary database on membrane protein abundance, with around 7,000[…]
SOPHIA ANTIPOLIS, France – April 3rd, 2025 │ March 11th, Bristol Myers Squibb (BMS) announced a definitive merger agreement to acquire all of the outstanding shares of 2seventy bio for a total equity value of approximately $286 million. The company 2seventy bio decided to focus exclusively on Abecma which was the first B cell maturation[…]
SOPHIA ANTIPOLIS, France – March 7, 2025 │ A few days ago, Regeneron decided to no longer seek accelerated approval of odronextamab, a bispecific antibody (bsAb) CD20 x CD3, for relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL). However, the company is continuing to pursue this approval for follicular lymphoma (FL), with an FDA[…]